Neurogene Inc
NGNE
NASDAQ
Biotechnology
$36.14
USD
+0.51 (+1.43%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $719.91M
Volume 115.9K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-111.11M
TTM
-31.7%
YoY
Operating Cash Flow
$-86.82M
TTM
-18.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | -100.0% | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 6.7 | 6.6 | 6.9 | 8.2 | 11.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 26.1 | 23.8 | 27.5 | 33.3 | 36.7 |
Operating Income | -26.1 | -23.8 | -27.5 | -33.3 | -36.7 |
EBITDA | -25.3 | -23.0 | -26.8 | -32.5 | -35.9 |
Other Income / Expense | 1.1 | 0.1 | 0.1 | 0.2 | 0.1 |
Total Other Income / Expense | 4.1 | 2.8 | 2.8 | 2.4 | 2.2 |
Income Before Income Taxes | -22.0 | -21.0 | -24.7 | -30.9 | -34.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -22.0 | -21.0 | -24.7 | -30.9 | -34.5 |
Consolidated Net Income / Loss | -22.0 | -21.0 | -24.7 | -30.9 | -34.5 |
Net Income Attributable to Common Shareholders | -22.0 | -21.0 | -24.7 | -30.9 | -34.5 |
Basic EPS | -$1.05 | -$0.99 | -$1.12 | -$1.39 | -$1.53 |
Diluted EPS | -$1.05 | -$0.99 | -$1.12 | -$1.39 | -$1.53 |
Basic Shares Outstanding | 21.1M | 21.2M | 22.1M | 22.3M | 22.6M |
Diluted Shares Outstanding | 21.1M | 21.2M | 22.1M | 22.3M | 22.6M |